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ABSTRACT 
 
Objectives: To analyse the genetic polymorphism of reverse transcriptase and protease genes in patients living with HIV-2, to search for possible 
mutations preventing the effectiveness of antiretroviral drugs (ARVs). 
Methods: RNA Viral was extracted after lysis of the virus particles and purified on filter columns (Qiagen). After their extraction, DNA fragments 
were amplified by the method of reverse transcription/polymerase chain reaction (RT/PCR) on one hand and by the PCR method enchase on the 
other hand. The study of genetic polymorphisms in reverse transcriptase and protease was performed after sequencing of amplicons. 
Results: A significant polymorphism was observed in positions involved in resistance to antiretrovirals. The most frequent was mutations M 46 I, M 
36 I/V, V82I, L 89 I on protease and Y 181 I, Y 188 L, G 190A on reverse transcriptase. 
Conclusion: Polymorphic mutations were observed in the genes of the protease and reverse transcriptase and could be involved in the HIV-2 
resistance to antiretrovirals (ARVs). It would be desirable to do the quantification of DNA provirus of HIV-2 in the other for a durable therapeutic 
monitoring of patients having HIV-2. 
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INTRODUCTION 
HIV Infection is a pandemic that affects more than 2.3 million people 
in the world with over 68% in sub-Saharan Africa. In West Africa, 
Côte d'Ivoire is one of the most affected countries with a prevalence 
of 3.4 % in the general population [1]. Discovered in 1983, HIV-1 is 
the first type of HIV identified and as the main agent responsible for 
the epidemie [2]. In 1986 a second type of HIV, HIV-2 was 
discovered in West Africa [3]. Epidemiological wise the latter is a 
minority, but still have a significant presence in West Africa, where it 
affects 1 to 2 million people [4, 5]. Its outbreak areas are located in 
Senegal, Guinea, Sierra Leone, Liberia and Côte D'Ivoire, are also 
found in India and Europe [2].  
The HIV-1 virus is very variable classified into four groups (M, O, N 
and P), the group M (Major) alone is responsible for over 95% of the 
pandemic [5]. HIV-2, also have several subtypes (A, B, C, D, E, F, G, H) 
Only subtypes A and B have an epidemic spread [6]. The progression 
of this HIV-2 type reveals the treatment management problems, 
encountered in the developing countries, in this case the monitoring 
of viral load [7, 8]. The treatment regimens prescribed in cases of 
HIV-1 are not always effective for HIV-2 [9]. There is no anti 
retroviral (ARV) treatment for patients infected with HIV-2 for now. 
Several observational studies in developing countries have shown 
poor results on ARV therapy for HIV-2 [10, 11].  
Therefore the epidemiological surveillance of HIV-2 strains is 
needed in order to improve the health care of people living with 
HIV-2. The aim of our study is to analyse the genetic polymorphism 
of reverse transcriptase and protease in patients with HIV-2, to 
search for possible mutations that  
MATERIALS AND METHODS 
Study site 
The study was initiated by the Laboratory of Biochemistry of the 
Faculty of Medical Sciences of the University of Felix Houphouet-
Boigny Abidjan. Our study was carried out in the molecular biology 
unit of the Laboratory of Virology of the Integrated Centre for 
Bioclinical research in Abidjan (ICBRA). 
Study population 
Were included in this study, patients with positive serology to HIV-2, 
naïve to major ARV, who gave their consent to participate in the 
study and signed a consent form. This study was approved by the 
National Ethics and Research Committee (NERC). Our study 
population consisted of a sample of 77 patients recruited between 
March 2009 and February 2010. 
Specimen collection and conservation 
After collecting information from patients, venous blood samples 
were collected in EDTA tubes. The tubes were centrifuged at 3500 
revolutions/min for 5 min. Four aliquots of 1 ml of plasma and two 
pellets of whole blood were stored at-80 °C. 
Calculation of phylogenetic trees 
Phylogenetic trees were calculated for each fragment using the 
methods of the Neighbor-Joining and Kimura of two-
parameters [12]. 
Gene amplification  
A polymorphism was observed in positions involved in the 
resistance to anti retrovirals. The most popular was the mutations in 
codons M 46, M 36, V 82 and L 89 on the protease gene and at the 
codons Y 181, Y 188 and G 190 for the reverse transcriptase gene. 
Molecular study 
RNA extraction 
RNA Viral was extracted after lysis of the virus particles and 
purified on filter columns (Qiagen), according to the method 
described by [13]. 
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Amplification of the HIV-2 polymerase gene (protease 
reverse transcriptase) by PCR 
Reverse transcription/polymerase chain reaction
The final volume of the first PCR was 50 µl and the amount of RNA 
patients was 10 µl. The reaction mixture consisted o
mother stock 20 µmol solutions of a pair of primers, 
of dNTP, 1 µl of RNase Inhibitor 5 U/µl, 1 µl of enzyme MIX, 10 µ
buffer 5 X, 2.5 µl of dithiothreitol (DTT) and MilliQ water qs. For 
these PCR, primer pair used was PR1-5'-GGG AAA GAA GCC CCG CAA 
CTT C-3’ and RT2-5'-GAA GTC GTC TGG GAT CCA CCA
CCA-3'. The thermal cycler was programmed to carry out an 
enzymatic activation and denaturation at 94 °C for 2 min, 40 cycles 
of amplification at the temperatures of (94 °
respectively for 30 s x 2 and 3 min and elongation at 68
Nested PCR 
For the second PCR, we have used as final volume 50
amount of DNA was 5 µl. The reaction mixture consisted o
of mother stock of 30 µmol solutions of a pair of primers, 
dNTP of 10 mmol, 0.4 µl of enzyme polymerase 
X buffer of 2.5 µl and MilliQ water qs. The second PCR was made 
with the pair of primers PR3-5’-GCT GCA CAA TTC CTC CTT TCT
and RT4-5’-TCC CCA AAT GAC TAG TGC TTC TTT TTC CTA T
thermocycler was programmed to perform: a reverse transcription 
at 94 °C for 3 min, 10 cycles of amplification at temperatures of (94
°C, 60 °C and 72 °C) respectively, for 15s, 30
amplification cycles at temperatures of (94 °
respectively for 30 s x 2 and 2 min and finally elongation at 72
7 min. 
Statistical analysis 
Sequence analysis of HIV-2 PCR has been aligned with the reference 
sequences of HIV-2 ROD. The wild type of protease has been defined 
by the alleles M 46, M 36, V 82 and L 89 and those of reverse 
transcriptase by alleles Y 181, Y 188 and G 190. The calculation of 
phylogenetic trees was performed with the REGA HIV 
Tool. 
RESULTS AND DISCUSSION  
Seventy-seven PCR were performed in this study. We got a 92% 
success rate (n = 71) and a failure rate of 8% (n = 6) (
seven patients were included in the study. 
(39%) (n = 30) were women and 61% (n = 47)
synthesis of different phylogenetic analysis showed that 53% (n = 
41) were strains of subtype A and 47% (n = 36) strains of subtype B 
of HIV-2, circulating in Abidjan (fig. 3). 
Phylogenetic analysis showed that 53 % (n = 41) were strains of 
subtype A, 47 % (n = 36) were subtype B strains
consistent with similar work carried out by several 
results confirmed the circulating subtypes A and B of HI
d’Ivoire [14, 15]. 
 
Fig. 1: Percentage of success of PCR
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I, M V 36 I/V, V 82 I, L 89 I on protease and Y 181 I, Y 188 L, G 190 
on reverse transcriptase (fig 4, 5).
A comparison of our sequences to that of reference sequences 
showed a polymorphism of the protease and reverse transcriptase 
genes which may be involved in HIV
(protease inhibitors and reverse transcriptase inhibitors). On the 
protease gene, the most common were M 46 I/V (methionine 
converted to Isoleucine or Valine at protease position 46), M 36 I 
(methionine converted to Isoleucine at protease position 36), V 82 I 
(valine converted to isoleucine at position 82) and L 89 I (leucine 
converted to Isoleucine at position 89). On the reverse transcriptase, 
polymorphism mutations Y 181 I (tyrosine converted to Isoleucine 
at position 181), Y 188 l (tyrosine converted to lysine at position 
188) et and G 190 A (Glycine converted to alanine at position 190) 
were the most represented. 
Fig. 2: Description of sex in the observational cohort
Fig. 3: Distribution of subtypes of HIV
phylogenetic trees in 
 
Regarding mutations of the polymorphism of 
studies done by Sabelle and Kevin in 2009 and 2011 respectively 
have confirmed our results. These results have shown that the 
mutation at codon M 46 I would be one of the 
induce resistance to protease inhibitors including indinavir (IDV) 
[16, 17]. The results of the study carried out by Weinberg in 2010, 
described mutations on codons M 46 I, M 36 I and V 82 I as 
mutations that could have an effect on the emergence of resistanc
to protease inhibitors [18]. These mutations observed in this gene 
have been cited in the study conducted by Ana in 2011, namely 
mutations at codons M 46 I, M 36 I, V 82 I and L 89 I. These results 
have shown that these mutations found in HIV
patients, are also known to induce resistance to protease inhibitors 
in HIV-1 patients. Conversion of methionine at position 46 to 
Isoleucine or Valine induces resistance to protease inhibitors [19].
Regarding the polymorphism mutations in the 
gene, they provide a natural resistance to non
transcriptase inhibitors. This indication is consistent with the work 
of authors like Alcaro in 2011 which stated that the mutation on the 
codon Y 181 I confers natural 
transcriptase inhibitors [20]. A study conducted by Ntemgwa in 
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resistance to non-nucleotide reverse 
 Y 188 L also 
induces this resistance thus confirming our results [15]
results were also observed for the codons Y 181 I, Y 188 L and G 190 
A which would be one of the mutations which induce resistance to 
non-nucleotide reverse transcriptase inhibitors
 
Fig. 4: Polymorphism of reverse transcriptase gene
 
Fig. 5: Polymorphism of protease gene
 
CONCLUSION 
These studies have enabled us to understand the genetic variability 
of HIV-2 and resistance to anti retroviral in patients 
retroviral treatments in Côte D'Ivoire. Phylogenetic analys
confirmed the circulation of HIV-2 subtypes A and B in
Polymorphism of mutations was observed in the genes of the 
protease and reverse transcriptase and may be involved in the 
resistance of HIV-2. It would therefore be necessary
HIV-2 proviral DNA in order for a durable therapeutic monitoring 
HIV-2 patients. 
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